These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 10505301)

  • 21. Cerivastatin gender effect: sub-analyses of results from a multinational, randomised, double-blind study. Cerivastatin Study Group.
    Ose L; Luurila O; Eriksson J; Olsson A; Lithell H; Widgren B
    Curr Med Res Opin; 2000; 16(2):80-7. PubMed ID: 10893651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance.
    Thompson PD; Rubino J; Janik MJ; MacDougall DE; McBride SJ; Margulies JR; Newton RS
    J Clin Lipidol; 2015; 9(3):295-304. PubMed ID: 26073387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes.
    Scharnagl H; Stojakovic T; Winkler K; Rosinger S; März W; Boehm BO
    Exp Clin Endocrinol Diabetes; 2007 Jun; 115(6):372-5. PubMed ID: 17701882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intense cholesterol lowering therapy with a HMG-CoA reductase inhibitor does not improve nitric oxide dependent endothelial function in type-2-diabetes--a multicenter, randomised, double-blind, three-arm placebo-controlled clinical trial.
    Balletshofer BM; Goebbel S; Rittig K; Enderle M; Schmölzer I; Wascher TC; Ferenc Pap A; Westermeier T; Petzinna D; Matthaei S; Häring HU
    Exp Clin Endocrinol Diabetes; 2005 Jun; 113(6):324-30. PubMed ID: 15977099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
    Robinson JG; Nedergaard BS; Rogers WJ; Fialkow J; Neutel JM; Ramstad D; Somaratne R; Legg JC; Nelson P; Scott R; Wasserman SM; Weiss R;
    JAMA; 2014 May; 311(18):1870-82. PubMed ID: 24825642
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia.
    Davidson MH; Donovan JM; Misir S; Jones MR
    Am J Cardiovasc Drugs; 2010; 10(5):305-14. PubMed ID: 20860413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor.
    von Keutz E; Schlüter G
    Am J Cardiol; 1998 Aug; 82(4B):11J-17J. PubMed ID: 9737641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pharmacy clinics. Medication of the month. Cerivastatin (Lipobay, Cholstat)].
    Scheen AJ
    Rev Med Liege; 2000 Feb; 55(2):117-20. PubMed ID: 10769583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cerivastatin.
    Cheng-Lai A
    Heart Dis; 2000; 2(1):93-9. PubMed ID: 11728245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol--a multinational, multicenter, double-blind study.
    Wu CC; Sy R; Tanphaichitr V; Hin AT; Suyono S; Lee YT
    J Formos Med Assoc; 2002 Jul; 101(7):478-87. PubMed ID: 12353340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.
    Bays HE; Ose L; Fraser N; Tribble DL; Quinto K; Reyes R; Johnson-Levonas AO; Sapre A; Donahue SR;
    Clin Ther; 2004 Nov; 26(11):1758-73. PubMed ID: 15639688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of age on the safety, tolerability, and pharmacokinetics of the novel HMG-CoA reductase inhibitor cerivastatin in healthy male volunteers.
    Mazzu A; Lettieri J; Kaiser L; Mullican W; Heller AH
    J Clin Pharmacol; 1998 Aug; 38(8):715-9. PubMed ID: 9725547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biopharmaceutical profile of cerivastatin: a novel HMG-CoA reductase inhibitor.
    Mück W; Ochmann K; Mazzu A; Lettieri J
    J Int Med Res; 1999; 27(3):107-14. PubMed ID: 10505300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects.
    Omori H; Nagashima H; Tsurumi Y; Takagi A; Ishizuka N; Hagiwara N; Kawana M; Kasanuki H
    Br J Clin Pharmacol; 2002 Oct; 54(4):395-9. PubMed ID: 12392587
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.
    Stein EA; Gipe D; Bergeron J; Gaudet D; Weiss R; Dufour R; Wu R; Pordy R
    Lancet; 2012 Jul; 380(9836):29-36. PubMed ID: 22633824
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gemfibrozil greatly increases plasma concentrations of cerivastatin.
    Backman JT; Kyrklund C; Neuvonen M; Neuvonen PJ
    Clin Pharmacol Ther; 2002 Dec; 72(6):685-91. PubMed ID: 12496749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
    Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
    JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
    Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
    Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of HMG-CoA reductase with cerivastatin lowers dense low density lipoproteins in patients with elevated fasting glucose, impaired glucose tolerance and type 2 diabetes mellitus.
    Scharnagl H; Winkler K; Mantz S; Baumstark MW; Wieland H; März W
    Exp Clin Endocrinol Diabetes; 2004 May; 112(5):269-77. PubMed ID: 15146374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.